These patents cover the use of vafidemstat for the treatment of psychiatric disorders such as Borderline Personality Disorder (BPD) and Attention Deficit Hyperactivity Disorder (ADHD).
![[Img # 58230]](https://empresaexterior.com/upload/images/07_2024/9996_laboratorio.jpg)
Oryzon Genomics S.A., a clinical-stage biopharmaceutical company specialized in epigenetics, has received the “Award decision"By the Japanese Patent Office (JPO) for two patents related to its compound vafidemstat.
The patent applications, JP2021-556616 and JP2021-556629, are titled “Methods of treatment of borderline personality disorder” and “Methods of treatment of attention deficit hyperactivity disorder using KDM1A inhibitors such as the compound vafidemstat,” respectively. . The patents, once granted, will not expire until at least 2040, with the possibility of additional extensions for greater protection.
The Grant Decision is a formal communication from the JPO indicating that the patent application has reached the stage where it is ready to be granted as a patent.
Oryzon has also recently received decisions granting the European and Korean Patent Offices for vafidemstat, covering its use in the treatment of aggression and social withdrawal, in addition to a corresponding patent granted in Russia.
Neus Virgili, Director of Industrial Property at Oryzon, commented: “We are very pleased to have obtained the Grant Decision for these two Japanese patent applications, which further reinforce the multi-layer protection strategy that we have built around vafidemstat.”
In turn, the Dr. Carlos Buesa, CEO of Oryzon, stated: “Our growing patent portfolio reinforces vafidemstat's unique value proposition, substantially expanding its commercial life in CNS indications with high market potential such as BPD and ADHD.”
